» Articles » PMID: 33502544

[Maculopathy in Sickle Cell Disease]

Overview
Journal Ophthalmologe
Specialty Ophthalmology
Date 2021 Jan 27
PMID 33502544
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sickle cell disease (SCD) is a hereditary hemoglobinopathy, which leads to microcirculatory disturbances of various organ systems through recurrent vaso-occlusive episodes, with a possibly fatal outcome. Sickle cell retinopathy (SCR) is the best described ocular manifestation of SCD. Irrespective of the presence of peripheral SCR, sickle cell maculopathy (SCM) can occur early in the course of the disease.

Methods: Review of the international and German literature on ocular involvement in SCD with a focus on SCR and SCM and an overview of current systemic therapeutic approaches in SCD on the occasion of the presentation of two patients with HbSS SCD.

Results And Conclusion: In contrast to SCR, SCM with temporal thinning of the inner retinal layers has only been increasingly described in the literature in the last 5 years, with the advent of SD-OCT and OCTA. Irrespective of the presence of SCR, as many as about half of the patients may develop SCM early in the course of the disease. As a result of progress in systemic therapeutic options and due to migration, the clinical picture will occur more often also in Germany. By knowing about this complication of SCD an early diagnosis can be made and unnecessary diagnostics can be avoided.

Citing Articles

Relationship between paramacular thinning, cerebral vasculopathy, and hematological risk factors in sickle cell disease.

Orssaud C, Flamarion E, Michon A, Ranque B, Arlet J Front Med (Lausanne). 2023; 10:1226210.

PMID: 37700770 PMC: 10493280. DOI: 10.3389/fmed.2023.1226210.


Sickle Cell Trait Presenting as Unilateral Proliferative Retinopathy and Macular Thinning in a Pregnant Woman.

Ghods S, Khalili Pour E, Faghihi H, Gharehbaghi G, Mirshahi A, Ghassemi F Case Rep Ophthalmol Med. 2021; 2021:5988889.

PMID: 34931150 PMC: 8684531. DOI: 10.1155/2021/5988889.

References
1.
Inamoto Y, Petricek I, Burns L, Chhabra S, DeFilipp Z, Hematti P . Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2018; 54(5):648-661. PMC: 6497536. DOI: 10.1038/s41409-018-0339-6. View

2.
Savige J, Liu J, DeBuc D, Handa J, Hageman G, Wang Y . Retinal basement membrane abnormalities and the retinopathy of Alport syndrome. Invest Ophthalmol Vis Sci. 2009; 51(3):1621-7. PMC: 2868425. DOI: 10.1167/iovs.08-3323. View

3.
Chen R, Flynn Jr H, Lee W, Parke 3rd D, Isom R, Davis J . Vitreoretinal management and surgical outcomes in proliferative sickle retinopathy: a case series. Am J Ophthalmol. 2014; 157(4):870-875.e1. PMC: 3959584. DOI: 10.1016/j.ajo.2013.12.019. View

4.
Rahimy E, Kuehlewein L, Sadda S, Sarraf D . Paracentral Acute Middle Maculopathy: What We Knew Then and What We Know Now. Retina. 2015; 35(10):1921-30. DOI: 10.1097/IAE.0000000000000785. View

5.
Williamson T, Rajput R, Laidlaw D, Mokete B . Vitreoretinal management of the complications of sickle cell retinopathy by observation or pars plana vitrectomy. Eye (Lond). 2008; 23(6):1314-20. DOI: 10.1038/eye.2008.296. View